Review Article Beta-Blockers in the Management of Hypertension and/or Chronic Kidney Disease

Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Thisminireview provides current summaries of beta-blocker use in themanagement of hypertension and/or chronic kidney disease. Accumulated evidence suggests that atenolol is not sufficiently effective as a primary tool to treat hypertension. The less-than-adequate effect of beta-blockers in lowering the blood pressure and on vascular protection, and the unfavorable effects of these drugs, as compared to other antihypertensive agents, on themetabolic profile have been pointed out. On the other hand, in patients with chronic kidney disease, renin-angiotensin systemblockers are the drugs of first choice for achieving the goal of renal protection. Recent studies have reported that vasodilatory beta-blockers have adequate antihypertensive efficacy and less harmful effects on the metabolic profile, and also exert beneficial effects on endothelial function and renal protection. However, there is still not sufficient evidence on the beneficial effects of the new beta-blockers. 1. Preface Several recent meta-analyses have questioned the usefulness of beta-blockers as the primary tools to treat hypertension [1–3]. This has led to hesitation in the proper use of beta-blockers in the management of hypertension and chronic kidney disease (CKD). This review describes the opinion base promoting the use of beta-blockers for the treatment of hypertension and CKD